The application of hyperthermia in regional chemotherapy

Franco Di Filippo, Michele Anzà, Carlo Riccardo Rossi, Francesco Cavaliere, Claudio Botti, Mario Lise, Rosa Garinei, Diana Giannarelli, Stefania Vasselli, Gabriella Zupi, Renato Cavaliere

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

To evaluate the role of hyperthermia combined with chemotherapy in the loco-regional treatment of tumors, a retrospective analysis was done with 228 limb melanoma patients treated with hyperthermic antiblastic perfusion (HAP). A series of treatment- and tumor-related prognostic factors was analyzed to establish their influence on tumor response, loco-regional control, and survival. Concerning tumor response, the logistic model showed that the number of lesions and the minimal tumor temperature (min T) maintained their individual predictive values (P <0.000001 and P = 0.04, respectively). For loco-regional control, only the number of lesions had a significant predictive value. No direct correlation was found between the treatment- related variables and loco-regional control. However, the 5-year survival rate was significantly higher for patients who achieved a complete response (CR) (51.5%, P = 0.0033) as compared to those who did not (33.3%), providing indirect evidence of the role of the treatment. Multivariate analysis showed that both disease-free and overall survival are strongly influenced by numerous clinical variables and the min T always maintained its significance. When analyzing the subgroup of 119 patients evaluable for tumor response, the Cox model selected the tumor response as the dominant factor for both disease-free and overall survival. These data seem to demonstrate that the optimization of treatment parameters is crucial in determining the CR rate, which, in turn, positively affects the disease outcome. HAP is the treatment of choice for recurrent limb melanoma, and hyperthermia plays an important role in exploiting the efficacy of this technique.

Original languageEnglish
Pages (from-to)215-223
Number of pages9
JournalSeminars in Surgical Oncology
Volume14
Issue number3
DOIs
Publication statusPublished - Apr 1998

Fingerprint

Fever
Drug Therapy
Neoplasms
Disease-Free Survival
Melanoma
Therapeutics
Extremities
Perfusion
Temperature
Proportional Hazards Models
Multivariate Analysis
Survival Rate
Logistic Models
Survival

Keywords

  • Antineoplastic agents
  • Clinical trials
  • Combined modality therapy
  • Extremities
  • Induced hyperthermia
  • Melanoma
  • Melphalan
  • Neoplasm staging
  • Prognosis
  • Regional perfusion
  • Survival rate
  • Tumor necrosis factor

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

The application of hyperthermia in regional chemotherapy. / Di Filippo, Franco; Anzà, Michele; Rossi, Carlo Riccardo; Cavaliere, Francesco; Botti, Claudio; Lise, Mario; Garinei, Rosa; Giannarelli, Diana; Vasselli, Stefania; Zupi, Gabriella; Cavaliere, Renato.

In: Seminars in Surgical Oncology, Vol. 14, No. 3, 04.1998, p. 215-223.

Research output: Contribution to journalArticle

Di Filippo, F, Anzà, M, Rossi, CR, Cavaliere, F, Botti, C, Lise, M, Garinei, R, Giannarelli, D, Vasselli, S, Zupi, G & Cavaliere, R 1998, 'The application of hyperthermia in regional chemotherapy', Seminars in Surgical Oncology, vol. 14, no. 3, pp. 215-223. https://doi.org/10.1002/(SICI)1098-2388(199804/05)14:3<215::AID-SSU5>3.0.CO;2-B
Di Filippo, Franco ; Anzà, Michele ; Rossi, Carlo Riccardo ; Cavaliere, Francesco ; Botti, Claudio ; Lise, Mario ; Garinei, Rosa ; Giannarelli, Diana ; Vasselli, Stefania ; Zupi, Gabriella ; Cavaliere, Renato. / The application of hyperthermia in regional chemotherapy. In: Seminars in Surgical Oncology. 1998 ; Vol. 14, No. 3. pp. 215-223.
@article{de4b331dcdea4b93a8049cd14e549757,
title = "The application of hyperthermia in regional chemotherapy",
abstract = "To evaluate the role of hyperthermia combined with chemotherapy in the loco-regional treatment of tumors, a retrospective analysis was done with 228 limb melanoma patients treated with hyperthermic antiblastic perfusion (HAP). A series of treatment- and tumor-related prognostic factors was analyzed to establish their influence on tumor response, loco-regional control, and survival. Concerning tumor response, the logistic model showed that the number of lesions and the minimal tumor temperature (min T) maintained their individual predictive values (P <0.000001 and P = 0.04, respectively). For loco-regional control, only the number of lesions had a significant predictive value. No direct correlation was found between the treatment- related variables and loco-regional control. However, the 5-year survival rate was significantly higher for patients who achieved a complete response (CR) (51.5{\%}, P = 0.0033) as compared to those who did not (33.3{\%}), providing indirect evidence of the role of the treatment. Multivariate analysis showed that both disease-free and overall survival are strongly influenced by numerous clinical variables and the min T always maintained its significance. When analyzing the subgroup of 119 patients evaluable for tumor response, the Cox model selected the tumor response as the dominant factor for both disease-free and overall survival. These data seem to demonstrate that the optimization of treatment parameters is crucial in determining the CR rate, which, in turn, positively affects the disease outcome. HAP is the treatment of choice for recurrent limb melanoma, and hyperthermia plays an important role in exploiting the efficacy of this technique.",
keywords = "Antineoplastic agents, Clinical trials, Combined modality therapy, Extremities, Induced hyperthermia, Melanoma, Melphalan, Neoplasm staging, Prognosis, Regional perfusion, Survival rate, Tumor necrosis factor",
author = "{Di Filippo}, Franco and Michele Anz{\`a} and Rossi, {Carlo Riccardo} and Francesco Cavaliere and Claudio Botti and Mario Lise and Rosa Garinei and Diana Giannarelli and Stefania Vasselli and Gabriella Zupi and Renato Cavaliere",
year = "1998",
month = "4",
doi = "10.1002/(SICI)1098-2388(199804/05)14:3<215::AID-SSU5>3.0.CO;2-B",
language = "English",
volume = "14",
pages = "215--223",
journal = "Seminars in Surgical Oncology",
issn = "8756-0437",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - The application of hyperthermia in regional chemotherapy

AU - Di Filippo, Franco

AU - Anzà, Michele

AU - Rossi, Carlo Riccardo

AU - Cavaliere, Francesco

AU - Botti, Claudio

AU - Lise, Mario

AU - Garinei, Rosa

AU - Giannarelli, Diana

AU - Vasselli, Stefania

AU - Zupi, Gabriella

AU - Cavaliere, Renato

PY - 1998/4

Y1 - 1998/4

N2 - To evaluate the role of hyperthermia combined with chemotherapy in the loco-regional treatment of tumors, a retrospective analysis was done with 228 limb melanoma patients treated with hyperthermic antiblastic perfusion (HAP). A series of treatment- and tumor-related prognostic factors was analyzed to establish their influence on tumor response, loco-regional control, and survival. Concerning tumor response, the logistic model showed that the number of lesions and the minimal tumor temperature (min T) maintained their individual predictive values (P <0.000001 and P = 0.04, respectively). For loco-regional control, only the number of lesions had a significant predictive value. No direct correlation was found between the treatment- related variables and loco-regional control. However, the 5-year survival rate was significantly higher for patients who achieved a complete response (CR) (51.5%, P = 0.0033) as compared to those who did not (33.3%), providing indirect evidence of the role of the treatment. Multivariate analysis showed that both disease-free and overall survival are strongly influenced by numerous clinical variables and the min T always maintained its significance. When analyzing the subgroup of 119 patients evaluable for tumor response, the Cox model selected the tumor response as the dominant factor for both disease-free and overall survival. These data seem to demonstrate that the optimization of treatment parameters is crucial in determining the CR rate, which, in turn, positively affects the disease outcome. HAP is the treatment of choice for recurrent limb melanoma, and hyperthermia plays an important role in exploiting the efficacy of this technique.

AB - To evaluate the role of hyperthermia combined with chemotherapy in the loco-regional treatment of tumors, a retrospective analysis was done with 228 limb melanoma patients treated with hyperthermic antiblastic perfusion (HAP). A series of treatment- and tumor-related prognostic factors was analyzed to establish their influence on tumor response, loco-regional control, and survival. Concerning tumor response, the logistic model showed that the number of lesions and the minimal tumor temperature (min T) maintained their individual predictive values (P <0.000001 and P = 0.04, respectively). For loco-regional control, only the number of lesions had a significant predictive value. No direct correlation was found between the treatment- related variables and loco-regional control. However, the 5-year survival rate was significantly higher for patients who achieved a complete response (CR) (51.5%, P = 0.0033) as compared to those who did not (33.3%), providing indirect evidence of the role of the treatment. Multivariate analysis showed that both disease-free and overall survival are strongly influenced by numerous clinical variables and the min T always maintained its significance. When analyzing the subgroup of 119 patients evaluable for tumor response, the Cox model selected the tumor response as the dominant factor for both disease-free and overall survival. These data seem to demonstrate that the optimization of treatment parameters is crucial in determining the CR rate, which, in turn, positively affects the disease outcome. HAP is the treatment of choice for recurrent limb melanoma, and hyperthermia plays an important role in exploiting the efficacy of this technique.

KW - Antineoplastic agents

KW - Clinical trials

KW - Combined modality therapy

KW - Extremities

KW - Induced hyperthermia

KW - Melanoma

KW - Melphalan

KW - Neoplasm staging

KW - Prognosis

KW - Regional perfusion

KW - Survival rate

KW - Tumor necrosis factor

UR - http://www.scopus.com/inward/record.url?scp=6844240240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6844240240&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1098-2388(199804/05)14:3<215::AID-SSU5>3.0.CO;2-B

DO - 10.1002/(SICI)1098-2388(199804/05)14:3<215::AID-SSU5>3.0.CO;2-B

M3 - Article

VL - 14

SP - 215

EP - 223

JO - Seminars in Surgical Oncology

JF - Seminars in Surgical Oncology

SN - 8756-0437

IS - 3

ER -